This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Awards highlight Avantor's commitment to the Biopharma industry
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Subscribe To Our Newsletter & Stay Updated
